PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-313.81%
Negative net income growth while TRVN stands at 21.37%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
289.12%
SBC growth well above TRVN's 31.64%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-122.10%
Both reduce yoy usage, with TRVN at -575.57%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
113.90%
AP growth of 113.90% while TRVN is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
-180.39%
Both reduce yoy usage, with TRVN at -575.57%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
2618.61%
Some yoy increase while TRVN is negative at -258.42%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
17.02%
Some CFO growth while TRVN is negative at -55.94%. John Neff would note a short-term liquidity lead over the competitor.
-23.76%
Both yoy lines negative, with TRVN at -88.26%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.76%
Both yoy lines negative, with TRVN at -88.26%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
-278.89%
We cut debt repayment yoy while TRVN is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.